174669-74-0Relevant articles and documents
[18F]FPyKYNE, a fluoropyridine-based alkyne reagent designed for the fluorine-18 labelling of macromolecules using click chemistry
Kuhnast, Bertrand,Hinnen, Francoise,Tavitian, Bertrand,Dolle, Frederic
, p. 336 - 342 (2008)
FPyKYNE (2-fluoro-3-pent-4-yn-1-yloxypyridine) is a novel fluoropyridine-based structure, designed for the fluorine-18 labelling of macromolecules using copper-catalysed Huisgen 1,3-dipolar cycloaddition (click chemistry). FPyKYNE (non-labelled as reference), as well as the 2-bromo, 2-nitro and 2-trimethylammonium analogues (as precursors for labelling with fluorine-18), was synthesized in 44, 95, 60 and 41%, respectively, from commercially available 5-chloropent-1-yne and the appropriate 2-substituted-3-hydroxypyridines. [18F]FPyKYNE was synthesized in one single radiochemical step by reaction of no-carrier-added K[ 18F]F-Kryptofix 222 (DMSO, 165°C, 3-5 min) followed by C-18 SepPak cartridge pre-purification and finally semi-preparative HPLC purification on a Hewlett Packard SiO2 Zorbax Rx-SIL. Using the 2-nitropyridine or the pyridin-2-yltrimethylammonium trifluoromethanesulphonate precursor for labelling (30 and 10 μmol, respectively), incorporation yields up to 90% were observed and 7.0-8.9 GBq (190-240 mCi) of [18F]FPyKYNE ([18F]-1) could be isolated within 60-70 min (HPLC purification included), starting from a 37.0 GBq (1.0 Ci) [18F]fluoride batch (overall decay-corrected and isolated yields: 30-35%). Copyright
Synthesis of a radiotracer for studying nicotinic acetylcholine receptors: 2-[18F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[18F]A- 85380)
Horti, Andrew G.,Koren, Andrei O.,Ravert, Hayden T.,Musachio, John L.,Mathews, William B.,London, Edythe D.,Dannals, Robert F.
, p. 309 - 318 (1998)
The radiochemical synthesis of 2-[18F]fluoro-3-(2(S)- azetidinylmethoxy)pyridine (2-[18F]A-85380, [18F]1) was accomplished by Kryptofix 222 assisted nucleophilic no-carrier-added [18F]fluorination of 2-iodo-3-((1-tert-butoxycarbonyl-2(S)-azetidinyl)methoxy)pyridine, 2 followed by acidic deprotection. The average radiochemical yield was 10% and the average specific radioactivity was 1050 mCi/μmol, calculated at end-of- synthesis (EOS).
Cu(I)/sucrose-catalyzed hydroxylation of arenes in water: The dual role of sucrose
Murata, Shigeo,Takagi, Mio,Takita, Ryo,Watanabe, Ayako,Watanabe, Kohei
supporting information, p. 7827 - 7831 (2020/11/02)
A protocol for the hydroxylation of aryl halides catalyzed by copper(I) and sucrose in neat water has been developed. The dual role of sucrose, the reaction pathway, and the high selectivity for hydroxylation were investigated using a combination of experimental and theoretical techniques. This journal is
A novel 2-cyanobenzothiazole-based 18F prosthetic group for conjugation to 1,2-aminothiol-bearing targeting vectors
Inkster, James A.H.,Colin, Didier J.,Seimbille, Yann
supporting information, p. 3667 - 3676 (2015/03/30)
In a bid to find an efficient means to radiolabel biomolecules under mild conditions for PET imaging, a bifunctional 18F prosthetic molecule has been developed. The compound, dubbed [18F]FPyPEGCBT, consists of a 2-substituted pyridine moiety for [18F]F- incorporation and a 2-cyanobenzothiazole moiety for coupling to terminal cysteine residues. The two functionalities are separated by a mini-PEG chain. [18F]FPyPEGCBT could be prepared from its corresponding 2-trimethylammonium triflate precursor (100 °C, 15 min, MeCN) in preparative yields of 11% ± 2 (decay corrected, n = 3) after HPLC purification. However, because the primary radiochemical impurity of the fluorination reaction will not interact with 1,2-aminothiol functionalities, the 18F prosthetic could be prepared for bioconjugation reactions by way of partial purification on a molecularly imprinted polymer solid-phase extraction cartridge. [18F]FPyPEGCBT was used to 18F-label a cyclo-(RGDfK) analogue which was modified with a terminal cysteine residue (TCEP·HCl, DIPEA, 30 min, 43°C, DMF). Final decay-corrected yields of 18F peptide were 7% ± 1 (n = 9) from end-of-bombardment. This novel integrin-imaging agent is currently being studied in murine models of cancer. We argue that [18F]FPyPEGCBT holds significant promise owing to its straightforward preparation, 'click'-like ease of use, and hydrophilic character. Indeed, the water-tolerant radio-bioconjugation protocol reported herein requires only one HPLC step for 18F peptide purification and can be carried out remotely using a single automated synthesis unit over 124-132 min.
Novel synthetic approach to fluoro- and amido-disubstituted 3-hydroxypyridin-4-ones
Ma, Yongmin,Hider, Robert C.
, p. 29 - 34 (2015/04/27)
Starting from fluoropyridines as a building block, with chelating functional groups being introduced, several fluoro- and amido-disubstituted 3-hydroxypyridin-4-ones have been synthesized with the intention of improving the pharmaceutical profile of 3-hydroxypyridin-4-ones.
Design and synthesis of fluorinated iron chelators for metabolic study and brain uptake
Ma, Yongmin,Roy, Sourav,Kong, Xiaole,Chen, Yulin,Liu, Dingyong,Hider, Robert C.
supporting information; experimental part, p. 2185 - 2195 (2012/05/04)
A range of fluorinated 3-hydroxypyridin-4-ones has been synthesized where fluorine or fluorinated substituent was attached at 2- or 5- position of the pyridine ring in order to improve chemical and biological properties of 3-hydroxypyridin-4-ones. The synthetic route is different from conventional counterparts where a functional group is introduced to a preformed 3-hydroxypyridin-4-one ring. Herein, we introduce a novel method which starts with a fluorine containing precursor and the two hydroxyl groups at 3- and 4- positions of the pyridine ring are introduced at a later stage. The pK a values of the free ligands and the affinity constants of their iron complexes demonstrate that the presence of fluorine dramatically alters the values. The distribution coefficient values of the free ligands and corresponding iron(III) complexes between 1-octanol and MOPS buffer (pH 7.4) are also influenced. Glucuronidation and oxidation studies of selected fluorinated 3-hydroxypyridin-4-ones demonstrate that some such fluorinated compounds have clear advantage over deferiprone in that they are metabolized more slowly. Blood-brain barrier permeability studies indicated that although lipophilicity influences the permeability it is not the only factor. Two of the selected seven fluorinated 3-hydroxypyridin-4-ones have improved brain distribution when compared with deferiprone.
BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS
-
Page/Page column 64, (2010/03/02)
The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.
Design and synthesis of fluorine-substituted 3-hydroxypyridin-4-ones
Ma, Yong Min,Hider, Robert C.
scheme or table, p. 5230 - 5233 (2010/11/03)
The presence of fluorine in an organic molecule can dramatically alter its chemical and biological properties due to its unique characteristics. Several 2- and 5-fluorine-substituted 3-hydroxypyridin-4-ones have been synthesised with the intention of improving the pharmaceutical profile of deferiprone.
OXAZOLOBENZIMIDAZOLE DERIVATIVES
-
Page/Page column 45, (2009/12/23)
The present invention is directed to oxazolobenzimidazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
FLUORINATED PYRIDIN-4-0NES
-
Page/Page column 15-16, (2009/10/18)
Metal chelating compounds of formula (I) are provided: or tautomers thereof or a pharmaceutically acceptable salt of either characterised in that R1 is selected from the group H and C1-6 alkyl R2, R4 and R5 are independently selected from the group H, C1-6 alkyl, Cl, F, -CHF2, CF3, -C(O)CF3, -CH(OH)CF3 and R6 R3 is selected from the group H, C1-6 alkyl and C1-6 acyl R6 is a group -C(O)-N(R7)(R8) R7 is selected from H and C1-6 alkyl and R8 is selected from H, C1-6 alkyl and a group -CH(R9CO)-N(R10XR11 ). R9 and R10 are independently selected from H, C1-6 alkyl and C1-10 aralkyl and R11 is selected from H and C1-6 alkyl, or R10 and R11 together with the nitrogen to which they are bonded form a 3-8 membered heterocyclic ring wherein at least one of R2, R4 and R5 is F. The compounds of the invention have reduced susceptibility to glucuronidation and microsomal oxidation as compared to current clinical compounds of the same class but in preferred forms have lower molecular weight and have blood brain barrier permeability.
